Risperidone
Synonyms / Brand Names: Risperidona, Risperidonum, Risperdal, Risperdal Consta, Risperdal M-Tab, Risperidal M-Tab, Risperin, Rispolept, Rispolin, Sequinan
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosing and Administration
Schizophrenia
- Usual initial dose: Risperidone can be administered on either a BID or a QD schedule. In early clinical trials, Risperidone was generally administered at 1 mg BID initially, with increases in increments of 1 mg BID on the second and third day, as tolerated, to a target dose of 3 mg BID by the third day. Subsequent controlled trials have indicated that total daily Risperidone doses of up to 8 mg on a QD regimen are also safe and effective. However, regardless of which regimen is employed, in some patients a slower titration may be medically appropriate. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for the active metabolite would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, small dose increments/decrements of 1–2 mg are recommended.
Bipolar mania
- Usual dose: Risperidone should be administered on a once daily schedule, starting with 2 mg to 3 mg per day. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours and in dosage increments/decrements of 1 mg per day, as studied in the short-term, placebo-controlled trials. In these trials, short-term (3 week) anti-manic efficacy was demonstrated in a flexible dosage range of 1–6 mg per day. Risperidone doses higher than 6 mg per day were not studied.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Risperidone
Return to top
Publication Resources
Most Recent Articles on Risperidone
Review Articles on Risperidone
Articles on Risperidone in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Risperidone
Return to top
Trial Resources
Ongoing Trials with Risperidone at Clinical Trials.gov
Trial Results with Risperidone
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Risperidone
Cochrane Collaboration on Risperidone
Cost Effectiveness of Risperidone
Return to top
Media Resources
Powerpoint Slides on Risperidone
Images of Risperidone
Podcasts & MP3s on Risperidone
Videos on Risperidone
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Risperidone
Discussion Groups on Risperidone
Patient Handouts on Risperidone
Blogs on Risperidone
Risperidone in the News
Risperidone in the Marketplace
Return to top
International Resources
Risperidone en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies